Weight loss was similar in patients on CSII, with a mean weight loss of 6.3 kg ( 2
Potential Benefits Joint pain and injury: used clinically for knee, shoulder, wrist, and hip conditions including arthritis, tendon injuries, cartilage damage, and general joint discomfort, via both subcutaneous and intra-articular injection protocols Musculoskeletal trauma: prescribed for fractures (including hairline fractures of the foot), wrist injuries, muscle strains, tendon damage, and soft tissue injuries to support structural and functional recovery Post-surgical recovery: used following orthopedic and other surgical procedures to support tissue repair at the operative site through angiogenesis, collagen synthesis, and inflammatory modulation Sports and exercise recovery: used by active patients experiencing slow recovery from training, muscle discomfort, and exercise-related soft tissue injuries, with the aim of shortening recovery time between sessions Gut health and systemic inflammation: investigated for gastrointestinal mucosal protection, reduction of systemic inflammatory markers, and tissue repair in patients with GI conditions or inflammatory presentations Degenerative joint conditions: prescribed for advanced degenerative joint changes and chronic pain conditions where conventional treatments have provided incomplete relief, including chronic knee and hip degeneration Skin healing and wound repair: prescribed for tissue regeneration and skin wound healing, including extended protocols for patients with significant skin healing requirements Tendon repair across multiple sites: shown in preclinical and emerging clinical research to support Achilles, patellar, rotator cuff, and deltoid tendon repair through collagen synthesis promotion and angiogenesis Anti-inflammatory effect on connective tissue: counteracts the anti-healing effects that NSAIDs and corticosteroids can impose on tendons and connective tissue, relevant for patients with prior steroid injection history Investigated for organ-protective properties in preclinical research, including liver, kidney, and cardiac tissue following injury or ischemic events Speak with a physician Interested in BPC-157
Although not originally developed for weight loss, many patients lose significant weightsome up to 25 pounds
Patients with a dual therapy with metformin and a DPP-4 inhibitor can also receive a further treatment intensification with a SGLT-2 inhibitor or a TZD (7074)
Surprising GLP-1 side effects Commenting on which newly identified symptoms were the most surprising, Neil Sehgal, ME, MS, the studys first author and a doctoral student advised by Guntuku and Lyle Ungar, PhD, told Medical News Today :\ There were a few interesting findings
The primary objective of the trial was to confirm that treatment with semaglutide does not result in any unacceptable increase in cardiovascular risk as compared to placebo in adults with type 2 diabetes
